Pharma BD Deal Intelligence
A small, sound bolt-on: Sensus's Somavert became a durable 20+ year Pfizer niche product, but was subsumed into the 2003 Pfizer-Pharmacia mega-merger before Pharmacia ever ran it independently.
Full analysis, sources & comparables →Pharmacia exercised its 1999 option to buy the remaining ~80% of Sensus, taking a 3-cent-per-share Q1 charge with no further earnings impact for the year and…
Pegvisomant's selective GH-receptor antagonism positioned it as a complement, not a replacement, for somatostatin analogs in patients with inadequate…
Somavert addressed acromegaly patients refractory to somatostatin analogs and became a rare-disease franchise asset Pfizer inherited via the Pharmacia…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Acquired Sensus to gain pegvisomant (Somavert/Trovert) growth-hormone receptor antagonist for acromegaly. Value undisclosed.
A small, sound bolt-on: Sensus's Somavert became a durable 20+ year Pfizer niche product, but was subsumed into the 2003 Pfizer-Pharmacia mega-merger before Pharmacia ever ran it independently.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pharmacia Corporation / Sensus Drug Development Corporation (this deal) | 2001 | $65M | 60 |
| Pharmacia Corporation / The Upjohn Company | 1995 | $13.0B | 37 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. | 2001 | $589M | 82 |
← Browse all deals · How we score deals
More: 2001 deals